The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

A new nationwide study led by the Keck School of Medicine of USC aims to examine how Type 1 diabetes impacts children's brain ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

The menopause market is projected to increase at a CAGR of 5.10% between 2025 – 2033, with North America making up 4.9% ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked ...